Why the study?
The genetic determinants of heart failure and response to medical therapy remain unknown, motivating identification of genetic variants associated with therapy response.
Does genetic variation upstream of the hypocretin/orexin receptor-2 (HCRTR2) gene associate with left ventricular ejection fraction improvement in patients with heart failure receiving medical therapy?
Cohort (n=1,664)
Blinded echocardiography in animal experiments
Yes
Does genetic variation upstream of the hypocretin/orexin receptor-2 (HCRTR2) gene associate with left ventricular ejection fraction improvement in patients with heart failure receiving medical therapy?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We found this new receptor that looked very promising. But what I'm most proud of is that the team didn't stop there; they went on to validate it in another data set, explore its mechanism in cellular models and then test the effect in several different mouse models.”
“The exciting thing is that this gene is in a completely different neurohormonal axis -- a completely different pathway than what has been looked at previously. Nobody had ever studied heart function in relation to this gene.”
“Overall, the study by Perez et al. is powerful and provides a translational analysis in humans and mice for the involvement of the HCRTR2 gene in HF treatment response. These findings may have broader implications for the development of a new treatment that may 'eat away' at the epidemic of HF.”
This systems genomics study identifies the hypocretin/orexin receptor-2 (HCRTR2) pathway as a novel genetic determinant of myocardial recovery in human heart failure and demonstrates that orexin A agonism rescues cardiac function in a preclinical heart failure model.
BACKGROUND The genetic determinants of heart failure (HF) and response to medical therapy remain unknown. We hypothesized that identifying genetic variants of HF that associate with response to medical therapy would elucidate the genetic basis of cardiac function. OBJECTIVES This study sought to identify genetic variations associated with response to HF therapy. METHODS This study compared extremes of response to medical therapy in 866 HF patients using a genome-wide approach that informed the systems-based design of a customized single nucleotide variant array. The effect of genotype on gene expression was measured using allele-specific luciferase reporter assays. Candidate gene transcription-deficient mice underwent echocardiography and treadmill exercise. The ability of the target gene agonist to rescue mice from chemically-induced HF was assessed with echocardiography. RESULTS Of 866 HF patients, 136 had an ejection fraction improvement of 20% attributed to resynchronization(n = 83), revascularization (n = 7), tachycardia resolution (n = 2), alcohol cessation (n = 1), or medications (n = 43). Those with the minor allele for rs7767652, upstream of hypocretin (orexin) receptor-2 (HCRTR2), were less likely to have improved left ventricular function (odds ratio: 0.40 per minor allele; p = 3.29 × 10−5). In a replication cohort of 798 patients, those with a minor allele for rs7767652 had a lower prevalence of ejection fraction >35% (odds ratio:0.769 per minor allele; p = 0.021). In an HF model, HCRTR2-deficient mice exhibited poorer cardiac function, worse treadmill exercise capacity, and greater myocardial scarring. Orexin, an HCRTR2 agonist, rescued function in this HF mouse model. CONCLUSIONS A systems approach identified a novel genetic contribution to human HF and a promising therapeutic agent efficacious in an HF model.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2015) conducted a cohort in Heart failure (n=1,664). Minor allele of rs7767652 upstream of hypocretin/orexin receptor-2 (HCRTR2) vs. Major allele (C) of rs7767652 was evaluated on Absolute improvement in left ventricular ejection fraction >10% on medical therapy (OR 0.394 per minor allele, p=3.29 × 10−5).
Synapse has enriched 10 related papers. Consider them for comparative context: